

PCR FOCUS on BioResorbable Scaffold (BRS)

March 7-8 2013 at SS Rotterdam

Program Committee for PCR FOCUS on BVS

Antonio Bartorelli, J Fajadet, Hector Garcia-Garcia, Robert-Jan van Geuns, Yoshinobu Onuma, Patrick W. Serruys, Pieter Smits, Stephan Windecker, Michael Haude, Stephan Verheye, Ron Waksman, Ashok Seth, Jumbo Ge, Takeshi Kimura, William Wijns

Local Program Directors

Pieter Smits, Patrick W Serruys, Robert-Jan van Geuns

International Faculty

Alexander Abizaid, Antonio Bartorelli, Bernard Chevalier, Elazar Edelman, Josep Gomez-Lara, Michael Haude, Refat Jabara, Takeshi Kimura, Antoine Lafont, Detlef Mathey, Souji Nishio, Richard Rapoza, Régis Rieu, Ashok Seth, Michel Vert, Renu Virmani, Ron Waksman, Boris Warnack, Stephan Windecker, Joan Zeltinger

Venue

7-8 Mar 2013 (Thursday and Friday)

The SS Rotterdam

Derde Katendrechtse Hoofd

3007 GA Rotterdam – the Netherlands

EBAC CME accreditation (program to be submitted)

This program is accredited by the European Board for Accreditation in Cardiology (EBAC) for **xx** (accreditation in progress) hours of External CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

General Objectives of PCR Focus Group meetings:

- To hold an interactive forum with scientists, clinical investigators and customers who will debate the available data related to this new technology
- To teach the specific aspects of the practical application of this technology in clinical practice and discuss the potential added value
- To identify future areas of clinical application which requires further research
- To prepare a comprehensive summary of the technology as the foundation for “glimpse into the future” sessions at PCR courses

Specific Objectives for the PCR Focus on Bioresorbable Scaffolds meeting:

- To give an overview on current data available on bioresorbable scaffolds
- To provide insight on how bioresorbable scaffolds are different from the currently available metallic stents
- To produce an overview on new imaging techniques that enables improvement of implantation techniques with bioresorbable scaffolds
- To debate on applications of this new technology

Agenda: March 7th (Thursday) – March 8th 2013 (Friday)

08:00–08:05 Welcome and Objectives of FOCUS 2013

William Wijns

08:05–08:10 Welcome aboard the SS Rotterdam

R-J van Geuns

Session 1: Historical perspective and Change in paradigm

Chairmen: Ron Waksman– Patrick W Serruys

8:10-08:25 10 years of trials with metallic drug-eluting stents

What did we learn from history?

Stephan Windecker

10 + 5 min

08:25-08:40 Does a metallic cage really disrupt the physiology/ biology of vessel structure? A physiological point of view

Patrick W. Serruys

10 + 5 min

08:40-08:55 Arterial healing after DES implantation - Insights from intracoronary imaging

Lorenz Räber

10 + 5 min

08:55-09:10 Bioresorbable vascular scaffolds: They do their job and disappear

Ron Waksman

10 + 5 min

09:10-09 :30 Keynote lecture:
Anatomopathologist's view of the past and future of PCI
Renu Virmani
20 min

09:30-10:10 LIVE demonstration 1: long-term follow-up after BVS implant
Robert-Jan van Geuns

10:10-10:40 Coffee Break 30' (30')

Session 2 : The basics of bioresorption

Chairmen:E Edelman, Michel Vert, R Waksman and Patrick W Serruys

10:40-10:52 What are the requirements for bioresorbable scaffold? A clinician's point of view Pieter Smits (7 + 5 min)

10:52-11:07 What are the requirements for bioresorbable scaffold? A biomechanical engineer's point of view E Edelman (10 + 5 min)

11:07-11:22 ABC of bioresorbable polymers (aliphatic polymer: PLLA, PLGA, Caprolacton, Tyrosine, Acetylsalicylate) B. Rattner (10 + 5 min)

**11:22-11:37 ABC of bioresorbable metals (Mg, Iron)
Ron Waksman (10 + 5 min)**

Debate

11:37-11:42 Why I do not like bioresorbable metals? B. Rattner 5min

11:42-11:47 Why I do not like aliphatic polymers? Ron Waksman 5min

11:47- 12:00 What are the biological consequences of polymer or metal resorption in coronary arteries – R Virmani (8 + 5 min)

12:00-12:15 Discussion: P. W. Serruys, R. Rapoza, B. Rattner, Ron Waksman, E Edelman, Pieter Smits, Boris Warnack

12:15-13:00 LIVE CASE 2: Live from MC Erasmus – Thorax centre (for instance, large size vessel, possibly LM)

13:00-14:00 Lunch

Session 3: Update on clinical experience part 1

Chairmen: Michael Haude, Stephan Verheye, Stephan Windecker

14:00-14:15	Biotronik	DREAMS	M Haude
	(Including a recorded case presentation 5')		
14:15-14:30	Abbott	Cohort B 3Y	PWS
14:25-14:35	REVA	RESORB	Alex Abizaid

14:35-14:45 Q & A and Interactive discussion with the audience 10'

14:45-15:35 Live case: (A Colombo: from Milan) 50'

15:35-16:00 Coffee Break

Session 3: Update on clinical experience part 2

Chairmen: Antonio Bartorelli, William Wijns, A Kastrati

16:00-16:10	Elixir	DESSOLVE-Nx	S Verheye
16:10-16:20	ART-DIVA	FIM	A Lafont
16:20-16:30	Abbott	ABSORB Extend	B Chevalier

16:30-16:50 Q & A from audience and interactive discussion

Bioresorbable scaffolds for treatment of peripheral arterial disease

16:50-17:00 ESPRIT trial Dr Lammer (Austria)

17:00-17:10 STANCE trial (ARSENAL 480biomedical), 10min. Thomas Zeller

Session 4:

Strut fracture: frequency, predictors and impact on outcomes

Chairs: PW Serruys, R Virmani

**17:10-17:20 Is Strut Fracture/ discontinuity with BRS a misnomer, myth or reality?
Y. Onuma 10 min.**

**DEBATE on Acute scaffold fracture and Late scaffold discontinuity, Fact and "Factoid"
each 5 min sharp, (no more than 6 slides)**

17:20-25	ABSORB: "Acute should be avoided, chronic is benign"	R. Rapoza
17:25-28	3min. Expert challenge	
17:28-33	ART: "It does not exist with this technology"	A. Lafont
17:33-36	3min. Expert challenge	
17:36-41	Magnesium: "I can blow it up to 5mm"	M. Haude
17:41-44	3min. Expert challenge	
17:44-49	Elixir: "This technology is expandable"	S. Verheye
17:49-52	3min. Expert challenge	
17:52-57	REVA: So far, we didn't talk about it"	A. Abizaid

17:57-18:00 Expert challenge

18:00-18:20 Q & A and interactive discussion with the audience

18:20-18:38 What did you take home from today?

3 min	Elazar Edelman
3 min	Stephan Verhey
3 min	Michael Haude
3 min	Lorenz Raber
3 min	Antonio Bartorelli
3 min	Hector Garcia

2nd Day

Chairmen: R Virmani, E Edelman, R Waksman

8:15-8:30 What is the best animal model to test BRS?
Heleen van Beusekom 10 + 5 min

New preclinical data **5 min each, sharp, max 8 slides**

08:30-08:35	Elixir (?)	all TBD
08:35-08:40	ART	
08:40-08:45	Amaranth J. Granada	
08:45-08:50	Orbus Neich R. Cottone	
08:50-08:55	Huaan Biotech (Xinsorb)	Dr. Zhang
08:55-09:00	Meril Life Science	

09:00-09:15 Q&A from audience and interactive discussion

Update on preclinical data **5 min each, sharp, max 8 slides**

09:15-09:20	ABSORB	RENU	all TBD
09:20-09:25	Biotronik		
09:25-09:30	REVA		

09:30-09:40 Q&A from audience and interactive discussion

09:40-10:10 Coffee Break

Real world use of scaffolds in new patient/ lesions part 1

Chairmen: J Ormiston, A Kastrati, Patrick W Serruys

10:10-10:20	Observational cases from ASSURE	Detlef Mathey
10:20-10:30	Challenging case(s) from ABSORB FIRST	Ashok Seth
10:30-10:40	STEMI	Stephan Windecker
10:40-10:50	Non STEMI and non STE-ACS	Manel Sabaté
10:50-11:00	CTO	Serra
11:00-11:10	Left Main	A. Abizaid
11:10-11:40	Interactive discussion with the audience	

11:40-12:40 **Lunch**

Real world use of scaffolds in new patient/ lesions **part 2**

Chairmen: A. Abizaid, S. Windecker,

12:40-12:50	Diabetic population	A. Bartorelli
12:50-13:00	Calcified vessels	Diletti/ Santoso
13:00-13:10	Overlap and long lesions	V. Farooq
13:10-13:20	Bifurcation treatment	T Majwal
13:20-13:40	Sidebranch outcomes	T. Muramatsu
13:40-13:50	Thorax centre experience	RJ van Geuns
13:50-14:00	Antonio Colombo's practice	Antonio Colombo
14:00-14:45	Viewpoints on ...	

How can we treat sidebranches and bifurcation lesions with bioresorbable scaffolds?

J Ormiston, Ron Waksman, J Koolen, A. Lafont, S. Verheye, Y Onuma

Each makes his statement in 3 min with max 4 slides, followed by discussion

14:45-15:30 (TBD: Possibility of LIVE case)

15:30-16:00 Coffee break

Session: Which imaging modality to use for sizing and follow-up assessment

16:15-16:25	What do we see on angiography, QCA, IVUS-GS, IVUS-VH and OCT?	M Joner/ H Garcia-Garcia?
16:25-16:35	MSCT for follow-up of polymeric bioresorbable device for follow-up	K Nieman
16:35-16:45	Non-invasive imaging of metallic bioresorbable devices: Insights from DREAMS	Ron Waksman or M. Haude (TBD)

16:45-17:00 Antiplatelet therapy after BRS implantation - (Need to be specific for BRS) Y Onuma?

A Kastrati or Marco Valgimigli or M Sabaté

17:00-17:30 Interactive discussion with FOCUS participants

17:45 Adjourn